Could Johnson & Johnson’s talcum powder litigation, now in its second decade, come to an end in 2025? Or are more legal and legislative battles on the horizon? Johnson & Johnson enters the New ...

A man in Maine is suing pharmeceutical giant Johnson & Johnson for $25 million over the death of his wife, claiming that use of its “dangerous and defective” talcum powder caused her death.

Trusted Johnson & Johnson brands including Tylenol, Aveeno, Neutrogena, Listerine, and Band-Aid are set to fall under the new, independent company name in a next-chapter move of repurposing and ...

Johnson & Johnson (JNJ) closed the latest trading day at $144.62, indicating a +0.89% change from the previous session's end. The stock's change was more than the S&P 500's daily loss of 0.43%.

Johnson & Johnson remains a "Buy" for its stability and consistent dividends, despite short-term price fluctuations and modest growth expectations. Q3 2024 results showed a 5.2% sales increase but ...

Johnson & Johnson JNJ-0.50%decrease; red down pointing triangle agreed to acquire mental-illness drug developer Intra-Cellular Therapies ITCI-0.05%decrease; red down pointing triangle for about $ ...

Johnson & Johnson's stagnant price and bond-like behavior make it an income investment, but a market shift could boost its appeal in 2025. Value stocks, including JNJ, may gain favor as growth ...